Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg; hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; crospovidone; microcrystalline cellulose; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 160 mg; hydrochlorothiazide, quantity: 12.5 mg; amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; purified talc; macrogol 4000 - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - valsartan; hydrochlorothiazide - film-coated tablet - 160/12.5 mg/mg - angiotensin ii antagonists and diuretics; valsartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - valsartan; hydrochlorothiazide - film-coated tablet - 80/12.5 mg/mg - angiotensin ii antagonists and diuretics; valsartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - valsartan; hydrochlorothiazide - film-coated tablet - 160/25 mg/mg - angiotensin ii antagonists and diuretics; valsartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - valsartan; hydrochlorothiazide - film-coated tablet - 80 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; valsartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - valsartan; hydrochlorothiazide - film-coated tablet - 160 mg/25 milligram(s) - angiotensin ii antagonists and diuretics; valsartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - valsartan; hydrochlorothiazide - film-coated tablet - 160/12.5 mg/mg - angiotensin ii antagonists and diuretics; valsartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - valsartan; hydrochlorothiazide - film-coated tablet - 160/25 mg/mg - angiotensin ii antagonists and diuretics; valsartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - valsartan; hydrochlorothiazide - film-coated tablet - 160 mg /12.5 milligram(s) - angiotensin ii antagonists and diuretics; valsartan and diuretics